PBAC's latest decision on Desvenlafaxine succinate: Recommended with restriction (2008). Considered for Treatment of major depressive disorder (MDD), including prevention of relapse.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2008
Submissions
1
2008 → 2008
Eligible population
Adult outpatients with major depressive disorder.
Therapy area
Mental health
Line of therapy
Any
Evidence base
Meta-analysis
Primary endpoint
ORR
Key trials
Des 304, Des 306, Des 308, Ven 014, Ven 015, Ven 203, Ven 208, Ven 209, Ven 211, Ven 301, Ven 302, Ven 313, Ven 342, Ven 346, Ven 360, Ven 367
Comparator
venlafaxine
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.